Antibacterial and Antifungal Efficacy of Medium and Low Weight Chitosan-Shelled Nanodroplets for the Treatment of Infected Chronic Wounds.
Candida spp
Streptococcus pyogenes
chitosan nanodroplets
chronic wounds
methicillin-resistant Staphylococcus aureus
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
12
2021
accepted:
15
03
2022
entrez:
21
4
2022
pubmed:
22
4
2022
medline:
23
4
2022
Statut:
epublish
Résumé
Medium versus low weight (MW vs LW) chitosan-shelled oxygen-loaded nanodroplets (cOLNDs) and oxygen-free nanodroplets (cOFNDs) were comparatively challenged for biocompatibility on human keratinocytes, for antimicrobial activity against four common infectious agents of chronic wounds (CWs) - methicillin-resistant cNDs were characterized for morphology and physico-chemical properties by microscopy and dynamic light scattering. In vitro oxygen release from cOLNDs was measured through an oximeter. ND biocompatibility and ability to promote wound healing in human normoxic/hypoxic skin cells were challenged by LDH and MTT assays using keratinocytes. ND antimicrobial activity was investigated by monitoring upon incubation with/without MW or LW cOLNDs/cOFNDs either bacteria or yeast growth over time. The mechanical interaction between NDs and microorganisms was also assessed by confocal microscopy. LW cNDs appeared less toxic to keratinocytes than MW cNDs. Based on cell counts, either MW or LW cOLNDs and cOFNDs displayed long-term antimicrobial efficacy against cNDs exerted bacteriostatic and fungistatic effects, due to the presence of chitosan in the outer shell and independently of oxygen addition in the inner core. The duration of such effects strictly depends on the characteristics of each microbial species, and not on the molecular weight of chitosan in ND shells. However, LW chitosan was better tolerated by human keratinocytes than MW. For these reasons, the use of LW NDs should be recommended in future research to assess cOLND efficacy for the treatment of infected CWs.
Identifiants
pubmed: 35444418
doi: 10.2147/IJN.S345553
pii: 345553
pmc: PMC9015045
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Infective Agents
0
Antifungal Agents
0
Chitosan
9012-76-4
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1725-1739Informations de copyright
© 2022 Mandras et al.
Déclaration de conflit d'intérêts
Dr Adriano Troia reports a patent EP20140759310 in Health and Biomedical Technological area issued to Italy. The author reports no other conflicts of interest in this work.
Références
Int J Pharm. 2008 Apr 2;353(1-2):139-48
pubmed: 18164151
Int J Pharm. 2009 Aug 13;378(1-2):215-7
pubmed: 19501639
Molecules. 2021 Jun 17;26(12):
pubmed: 34204251
Int J Biol Macromol. 2020 Dec 1;164:2726-2744
pubmed: 32841671
J Chin Med Assoc. 2018 Feb;81(2):94-101
pubmed: 29169897
Int J Food Microbiol. 2001 Dec 30;71(2-3):235-44
pubmed: 11789941
Pharm Res. 2018 Feb 26;35(4):75
pubmed: 29484487
Cold Spring Harb Perspect Med. 2014 Sep 02;4(9):a019778
pubmed: 25183855
Adv Wound Care (New Rochelle). 2016 Oct 1;5(10):455-463
pubmed: 27785379
J Invest Dermatol. 2001 Jan;116(1):50-6
pubmed: 11168797
ACS Appl Mater Interfaces. 2015 Jan 21;7(2):1087-99
pubmed: 25522372
Pharm Sci Technol Today. 2000 Sep 1;3(9):318-326
pubmed: 10996573
Diabet Med. 2005 Aug;22(8):1124-5
pubmed: 16026387
Wound Repair Regen. 2009 Nov-Dec;17(6):763-71
pubmed: 19903300
BMC Microbiol. 2016 Sep 21;16(1):220
pubmed: 27654924
Microbes Infect. 2012 Apr;14(4):311-6
pubmed: 22133978
Microbiol Mol Biol Rev. 1999 Mar;63(1):174-229
pubmed: 10066836
J Intensive Care Med. 2010 Mar-Apr;25(2):78-92
pubmed: 19955115
Mar Drugs. 2021 Feb 15;19(2):
pubmed: 33672056
Environ Int. 2009 Feb;35(2):418-24
pubmed: 18845341
Biomaterials. 1998 Aug;19(16):1529-39
pubmed: 9794531
Pathophysiology. 2003 Jan;9(2):81-87
pubmed: 14567939
J Burn Care Res. 2008 Jan-Feb;29(1):213-21
pubmed: 18182925
J Colloid Interface Sci. 2003 May 15;261(2):402-10
pubmed: 16256549
Biomed Res Int. 2013;2013:527549
pubmed: 23844364
Can J Infect Dis Med Microbiol. 2008 Mar;19(2):173-84
pubmed: 19352449
Int J Food Microbiol. 2004 Sep 1;95(2):147-55
pubmed: 15282127
Future Microbiol. 2020 Sep;15:1227-1236
pubmed: 33026879
PLoS One. 2014 Mar 21;9(3):e92723
pubmed: 24658463
Adv Drug Deliv Rev. 2010 Jan 31;62(1):28-41
pubmed: 19874862
J Clin Microbiol. 2000 Feb;38(2):918-22
pubmed: 10655417
J Microbiol Biotechnol. 2019 Jul 28;29(7):1009-1013
pubmed: 31288302
PLoS Pathog. 2013;9(9):e1003550
pubmed: 24086128
Skin Pharmacol Physiol. 2010;23(3):117-23
pubmed: 20051712
Int J Nanomedicine. 2017 Dec 27;13:175-186
pubmed: 29343956
World J Diabetes. 2011 Feb 15;2(2):24-32
pubmed: 21537457
Small. 2018 May;14(21):e1704347
pubmed: 29682895
Annu Rev Microbiol. 2013;67:313-36
pubmed: 24024634
Adv Wound Care (New Rochelle). 2012 Dec;1(6):225-230
pubmed: 24527310
Skin Pharmacol Physiol. 2010;23(3):164-70
pubmed: 20110767
Mediators Inflamm. 2015;2015:964838
pubmed: 25878404
Int J Biol Macromol. 2021 Mar 1;172:154-161
pubmed: 33428951
Int J Pharm. 2009 Nov 3;381(2):160-5
pubmed: 19616610
PLoS One. 2015 Mar 17;10(3):e0119769
pubmed: 25781463
J Microbiol. 2011 Apr;49(2):171-7
pubmed: 21538235
Microbiol Mol Biol Rev. 1998 Mar;62(1):130-80
pubmed: 9529890
Adv Ther. 2017 Mar;34(3):599-610
pubmed: 28108895
Biosci Biotechnol Biochem. 2016;80(3):466-72
pubmed: 26523859
Adv Wound Care (New Rochelle). 2016 Jul 1;5(7):314-328
pubmed: 27366592
Adv Wound Care (New Rochelle). 2014 May 1;3(5):390-399
pubmed: 24804159
Future Microbiol. 2015;10(6):929-39
pubmed: 26059617
Toxicol Appl Pharmacol. 2015 Aug 1;286(3):198-206
pubmed: 25937238
Int Wound J. 2006 Sep;3(3):225-31
pubmed: 16984578